For Henry Ahc's mission is to fund research to develop a treatment for ahc. Our current main focus is funding research to develop an aso (antisnese oligonucleotide) treatment for a specific genetic mutation that causes ahc, which will forge a path for other aso's to be developed for other patients with ahc caused by other genetic mutations, as well as other similar genetic neurological diseases.
Largest programs · fiscal year 2025
Aso program: This program encompasses all preclinical work necessary to fund and devleop a human aso treatment. So far, this project has entailed wgs at illumina, aso sequence development at charles river laboratories, and the aso design and screening as well as functional electrophysiological studies led by dr. Tim yu's lab at Boston children's hospital in collaboration with dr. George's lab at n… Read more
Aso program: This program encompasses all preclinical work necessary to fund and devleop a human aso treatment. So far, this project has entailed wgs at illumina, aso sequence development at charles river laboratories, and the aso design and screening as well as functional electrophysiological studies led by dr. Tim yu's lab at Boston children's hospital in collaboration with dr. George's lab at northwestern. Included in this project are mouse tolerability and proof of concept studies at the rare disease translational center at the jackson laboratories. Mouse aso proof of concept studies: This project entails support for 3 mouse aso proof of concept studies at the rare disease translation center at the jackson laboratories which will benefit the entire ahc community by illustrating the best and worst case scenario for mouse phenotypic rescue with an aso design for mice, targeting 2 ahc causing mutations.
$1,132,948 spent · 100.0% of program spending
Drug repurposing studies: We have also funded work for a drug repurposing screen through a company called rareshift which has served as a pilot for our ahc community, in collaboration with two other projects funded by other ahc organizations. This project helps us better understand common pathways for medications that may be used to treat ahc, potentially across multiple mutations. The data result… Read more
Drug repurposing studies: We have also funded work for a drug repurposing screen through a company called rareshift which has served as a pilot for our ahc community, in collaboration with two other projects funded by other ahc organizations. This project helps us better understand common pathways for medications that may be used to treat ahc, potentially across multiple mutations. The data resulted from this screen will inform future drug repurposing studies in mice as well.
Where each dollar went · fiscal year 2025
Of every dollar it spent, 100¢ went to programs, 0¢ to management and 0¢ to fundraising.
Programs $1,132,948
Management $0
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$646,193Fiscal year 2025
Expenses$1,132,948Fiscal year 2025
Total assets$650,307Fiscal year 2025
Total liabilities$0Fiscal year 2025
Fiscal year ending December2025
Revenue$646,193
Expenses$1,132,948
Net income−$486,755
Net assets$650,307
Notable sources of revenue
Percent of total revenue
Contributions
$615,984
95.3%
Program services
$0
0.0%
Investment income
$30,209
4.7%
Other (net)
$0
0.0%
Assets / debt
Total assets
$650,307
Total liabilities
$0
Net assets
$650,307
Compensation
Not in our extract for this year.
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?